Checked
BioAtla, Inc.
OTC: BCAB · Biological Products, (No Diagnostic Substances) · San Diego, CA
- Net income
- -$59.61M
- Total assets
- $13.83M
- Diluted EPS
- -$1.01
Company details
As reported to the SEC
- SEC CIK
- 1826892
- Stock
- OTC: BCAB
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- Headquarters
- 11085 Torreyana Road, San Diego, CA 92121
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Non-accelerated filer, Smaller reporting company
- Phone
- (858) 558-0708
- Employer ID (EIN)
- 85-1922320
- Last annual report
- 03/31/2026
- Last quarterly report
- 08/13/2026
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | Not reported | Not reported | Not reported | Not reported | $300K |
| Operating income | -$59.3M | -$73.94M | -$129.7M | -$108.1M | -$96.44M |
| Net income | -$59.61M | -$69.78M | -$123.5M | -$106.5M | -$95.4M |
| Diluted earnings per share | -$1.01 | -$1.44 | -$2.58 | -$2.74 | -$2.76 |
| Research and development | $43.57M | $63.09M | $103.7M | $79.35M | $58.27M |
| Total assets | $13.83M | $52.42M | $119.7M | $225.7M | $254.4M |
| Total liabilities | $50.02M | $38.16M | $48.99M | $45.4M | $43.6M |
| Shareholders' equity | -$36.19M | $14.27M | $70.67M | $180.3M | $210.8M |
| Cash and cash equivalents | $7.12M | $49.05M | $111.5M | $215.5M | $245M |
| Cash from operations | -$48.2M | -$71.94M | -$104M | -$90.42M | -$62.21M |
Recent filings
104 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
17 insider ownership reports (Forms 3, 4, 5 and 144) were filed about BioAtla, Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other biological products, (no diagnostic substances)
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Amgen IncAMGN | Thousand Oaks, CA | $36.75B | $7.71B |
| Gilead Sciences, Inc.GILD | Foster City, CA | $29.44B | $8.51B |
| Biogen Inc.BIIB | Cambridge, MA | $9.89B | $1.29B |
| Neurocrine Biosciences IncNBIX | San Diego, CA | $2.86B | $478.6M |
| Exelixis, Inc.EXEL | Alameda, CA | $2.32B | $782.6M |
| Qiagen N.V.QGEN | Pl Venlo, Netherlands | $2.09B | $424.9M |
| Moderna, Inc.MRNA | Cambridge, MA | $1.94B | -$2.82B |
| Halozyme Therapeutics, Inc.HALO | San Diego, CA | $1.4B | $316.9M |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is BioAtla, Inc.'s CIK number?
- BioAtla, Inc.'s SEC Central Index Key (CIK) is 1826892.
- What is BioAtla, Inc.'s stock ticker?
- BioAtla, Inc. trades as OTC: BCAB.
- When does BioAtla, Inc.'s fiscal year end?
- BioAtla, Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is BioAtla, Inc. headquartered?
- BioAtla, Inc.'s principal executive office on file with the SEC is in San Diego, CA.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026